Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: A review

International Review of Psychiatry (Impact Factor: 1.8). 02/2014; 26(1):44-62. DOI: 10.3109/09540261.2013.842542
Source: PubMed


Abstract At least 25-30% of patients with cancer and an even higher percentage of patients in an advanced phase of illness meet the criteria for a psychiatric diagnosis, including depression, anxiety, stress-related syndromes, adjustment disorders, sleep disorders and delirium. A number of studies have accumulated over the last 35 years on the use of psychotropic drugs as a pillar in the treatment of psychiatric disorders. Major advances in psycho-oncology research have also shown the efficacy of psychotropic drugs as adjuvant treatment of cancer-related symptoms, such as pain, hot flushes, pruritus, nausea and vomiting, fatigue, and cognitive impairment. The knowledge about pharmacokinetics and pharmacodynamics, clinical use, safety, side effects and efficacy of psychotropic drugs in cancer care is essential for an integrated and multidimensional approach to patients treated in different settings, including community-based centres, oncology, and palliative care. A search of the major databases (MEDLINE, Embase, PsycLIT, PsycINFO, the Cochrane Library) was conducted in order to summarize relevant data concerning the efficacy and safety of pharmacotherapy for cancer-related psychiatric disorders in cancer patients across the trajectory of the disease.

Download full-text


Available from: Luigi Grassi, Apr 09, 2014
80 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The chapter provides a summary of the main issues related to the assessment of the psychological reactions and/or psychopathological disorders in oncology and palliative care. A careful psychiatric interview and a proper mental status examination (MSE) are the means by which a psychiatric diagnosis is made, as a mandatory step when prescribing psychotropic drugs. During the assessment, a detailed description and evaluation of the emotional and behavioral signs and symptoms indicative of a psychiatric disturbance should be carried out. Several other variables need also to be considered (e.g., attachment styles, coping, defense mechanisms, stressful life events, social support) in order to fully understand the patient’s status. Furthermore, a definite assessment of the patient’s physical functioning and the general medical condition, in liaison with the healthcare professionals, is a necessary component of the psychiatric diagnostic process. The Diagnostic and Statistical Manual for Mental Disorders (DSM-5) and the International Classification of Diseases (ICD-10) are the most common taxonomic systems to classify psychiatric disorders. Changes in the diagnostic criteria, especially with regard to the rubrics of adjustment disorders, depressive disorders, somatic symptom disorders, and psychological factors affecting a medical condition, have however been proposed when the DSM or the ICD are applied in oncology and palliative care settings. The Diagnostic Criteria for Psychosomatic Research (DCPR) are useful for a more precise identification of psychosocial conditions affecting cancer patients, including health anxiety, demoralization, and somatic symptom presentation of distress. A psychosomatic integrative approach is thus necessary in the psychiatric diagnostic process.
    Psychopharmacology in Oncology and Palliative Care, 01/2014: pages 31-48; , ISBN: 978-3-642-40133-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: Depression, anxiety, delirium, and other psychiatric symptoms are highly prevalent in the cancer setting, and pharmacological intervention is an important component in the overall psychosocial care of the patient. Psychopharmacology is also used as a primary or adjuvant treatment for the management of cancer-related symptoms stemming from the disease itself and/or its treatment, including sleep disturbance, loss of appetite, neuropathic pain, nausea, fatigue, and hot flashes. Psychiatrists, oncologists, and palliative care physicians working as members of a multidisciplinary team have the opportunity to target multiple symptoms that negatively affect a patient's quality of life with the strategic use of psychotropic medications when deemed appropriate. This article aims to review the indications for use of antidepressants, psychostimulants, anxiolytics, antipsychotics, and mood stabilizers in oncology. An updated review of the relevant literature is discussed and referenced in each section.
    Current Psychiatry Reports 01/2015; 17(1):529. DOI:10.1007/s11920-014-0529-x · 3.24 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: More than half a century after their discovery, benzodiazepines (BDZs) still represent one of the largest and most widely prescribed groups of psychotropic compounds, not only in clinical psychiatry but also in the entire medical field. Over the last two decades, however, there has been an increased focus on the development of antidepressants and antipsychotics on the part of the pharmaceutical industry, clinicians, and researchers, with a reduced interest in BDZs, in spite of their widespread clinical use. As a consequence, many psychiatric residents, medical students, nurses, and other mental health professionals might receive poor academic teaching and training regarding these agents, and have the false impression that BDZs represent an outdated chapter in clinical psychopharmacology. However, recent advances in the field, including findings concerning epidemiology, addiction risk, and drug interactions, as well as the introduction of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition with related diagnostic changes, strongly encourage an updated appraisal of the use of BDZs in clinical practice. During a recent thematic event convened with the aim of approaching this topic in a critical manner, a group of young Italian psychiatrists attempted to highlight possible flaws in current teaching pathways, identify the main clinical pros and cons regarding current use of BDZs in clinical practice, and provide an updated overview of their use across specific clinical areas and patient populations. The main results are presented and discussed in this review.
    Neuropsychiatric Disease and Treatment 08/2015; 11:1885-909. DOI:10.2147/NDT.S83130 · 1.74 Impact Factor
Show more